EP1062231A1 - Process for the preparation of a tetrapeptide - Google Patents

Process for the preparation of a tetrapeptide

Info

Publication number
EP1062231A1
EP1062231A1 EP99910934A EP99910934A EP1062231A1 EP 1062231 A1 EP1062231 A1 EP 1062231A1 EP 99910934 A EP99910934 A EP 99910934A EP 99910934 A EP99910934 A EP 99910934A EP 1062231 A1 EP1062231 A1 EP 1062231A1
Authority
EP
European Patent Office
Prior art keywords
derivative
phe
group
ester
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99910934A
Other languages
German (de)
French (fr)
Inventor
Henry Franz N
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1062231A1 publication Critical patent/EP1062231A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N

Definitions

  • the present invention is directed to a new process for the preparation of a tetrapeptide, more specifically the tetrapeptide H-Tyr-D-Ala-Phe(pF)-Phe- NH2, or a pharmaceutically acceptable salt thereof.
  • the present invention also relates to new intermediates used in process.
  • the present invention relates to a new process for the preparation of the peptide H-Tyr-D- Ala-Phe(pF)-Phe-NH2' or a pharmaceutically acceptable salt thereof.
  • WO 97/07129 discloses a process for producing inter alia the peptide H-Tyr-D-Ala-Phe(pF)-Phe-NH 2 .
  • the peptide H-Tyr-D-Ala-Phe(pF)-Phe-NH is also disclosed in WO 97/07130.
  • Said peptide exhibits peripheral analgesic activity and selectivity for the ⁇ subtype of opioid receptors, and is suitable in particularly in pain therapy. Furthermore, it is prepared using solid phase synthesis according to procedures well established in the art.
  • the drawback with solid phase synthesis which is a common and well established method for peptide synthesis, is that it is difficult to use for large scale production, in addition to being expensive.
  • the process of the present invention provides the tetrapeptide H-Tyr-D-Ala-Phe(pF)-Phe- NH 2 with a higher purity, in a more cost effective and environmentally better way compared to methods known in the art. Furthermore, the process of the present application provides the product in a higher yield.
  • the object of the present invention is to provide a novel process suitable for use in large scale synthesis.
  • a further object of the present invention is to provide a process containing as few reaction steps as possible.
  • the present invention provides a new process for large scale preparation of the peptide H- Tyr-D-Ala-Phe(pF)-Phe-NH2, which is a peptide of the formula (I)
  • A is an amino protecting group
  • R is an activating agent residue group; previously prepared by a pre-activation step or generated in situ, is reacted with the amino group of phenylalanine, wherein the carboxyl group is protected as an ester or amide, i.e. a compound of the formula Phe-R , wherein R is the ester or amide residue group, in the presence of a solvent, providing a protected dipeptide derivative (TV)
  • A is an amino protecting group, and R is an ester or an amide residue group
  • R is an ester or an amide residue group
  • A is an amino protecting group
  • R is an activating agent residue group; previously prepared by a pre-activation step or generated in situ, is reacted with the product of step 1, i.e. the dipeptide derivative (5) in the presence of a solvent, providing the protected tripeptide derivative(VIII)
  • A is an amino protecting group
  • R is an ester or an amide residue group
  • R is an ester or an amide residue group
  • A is an amino protecting group
  • R is an activating agent residue group
  • A is an amino protecting group
  • R is an ester or an amide residue group
  • the peptide H-Tyr-D-Ala-Phe(pF)-Phe-NH2 (I), may if desired be reacted with a pharmaceutically acceptable acid, such as AcOH, H3PO4, citric acid, lactic acid and HCI.
  • HCI is the preferred acid to use in accordance with the present invention. Possible salts which may be used are described in S. M. Berge, L. D. Bighley and D. C. Monkhouse, J. Pharmaceut. Sci, 66(1977) 1-19.
  • Step 2 (i) A coupling step, (ii) A deprotection step
  • step 3(ii) could instead be performed after the coupling step (i) in Step 1 or step 2.
  • the transformation step is performed after the coupling step (i) in step 1.
  • the preferred way of performing the process of the present invention could therefore schematically be described as comprising the following steps;
  • Step 1 (i) A coupling step
  • Step 2 (i) A coupling step, (ii) A deprotection step
  • the N -amino protecting group may be selected from any protecting group suitable in peptide synthesis, such as tert-butoxycarbonyl (Boc) or benzyloxycarbonyl, often abbreviated Z-, just to mention two possible amino protecting groups.
  • benzyloxycarbonyl is particularly preferred to use for the present synthesis since it is easily removed by catalytic hydrogenation, and contrary to the protecting group Boc, it does not require neutralization of the liberated amine.
  • Suitable amino and carboxyl protecting groups which may be used in accordance with the present invention will be appreciated by a person skilled in the art. Reference is made to J. Meienhofer in The Peptides, Vol.l, Eds.: E. Gross & J.
  • the pre-activation step preceding Step 1-3, or the in situ generation of the activated activated amino acid derivative is achieved by reacting an amino acid, wherein the amino function has been protected by a suitable protecting group, such as tert-butoxycarbonyl (Boc) or benzyloxycarbonyl (Z), which are either commercially available or available by techniques known in the art, with an activating agent in the presence of a tertiary amine and an organic solvent, providing the activated amino acid derivative.
  • a suitable protecting group such as tert-butoxycarbonyl (Boc) or benzyloxycarbonyl (Z)
  • A is an amino protecting group
  • R is an activating agent residue group
  • Step 1-3 a variety of powerful solvents may be used, as long as the amino component is essentially soluble and available for immediate reaction with the activated peptide derivative.
  • suitable solvents for the coupling step are acetone, acetonitrile, DMF, N-methyl pyrrolidone (NMP) and EtOAc, or mixtures thereof.
  • benzyl-like group denotes any substituted or un-substituted benzyl group that is hydrogenolyzed under similar reaction conditions as the benzyloxycarbonyl group.
  • Suitable activating agents may be selected from those that generates any of the commonly used activated amino acid derivatives including, but not limited to, carbodiimides, activated esters, azide, or anhydrides.
  • Isobutylchloroformiate iBuOCOCl
  • isobutylchloroformiate iBuOCOCl
  • the activated peptide derivative will have the following structure, exemplified on D-alanine,
  • the tertiary amine may be selected from any tertiary amine.
  • NMM N-methylmorpholine
  • di-isopropylethylamine and triethylamine are preferred.
  • a secondary amine which is sterically hindered may also be used.
  • the organic solvent may be any organic solvent known to a person skilled in the art to be suitable in peptide chemistry. However, ethyl acetate, acetonitrile, acetone and tetrahydrofurane are preferred solvents in the pre-activation step.
  • the solvent used for the coupling step may be selected from a variety of solvents, as long as the amino component is essentially soluble and available for immediate reaction with the O 99/47548
  • Suitable solvents for the coupling steps are acetone, acetonitrile, DMF, N-methyl pyrrolidone (NMP) and EtOAc, or mixtures thereof, of which acetone, EtOAc, NMP and DMF are preferred.
  • any temperature where the activated amino acid derivative is not degraded or the reaction rate is too slow may be used.
  • the preferred range is from 0°C to -20°C, and particularly preferred is from -5°C to -15°C.
  • the rate of addition is adjusted so that the preferred temperature is maintained.
  • the catalyst used for hydrogenation may be selected from a great variety of catalysts as will be appreciated by a person skilled in the art. However 5% Pd on carbon is preferred. Any solvent that can dissolve at least some of the peptide is possible to use except ketones, such as acetone, or those solvents that poison the catalyst or react with the components of the reaction. The choice of solvent will be appreciated by a person skilled in the art. DMF is the preferred solvent.
  • Step 3(ii) is only required if the protected tetrapeptide derivative (XI) prepared in step 3(i) is an ester. Thus, if an amide of phenylalanine is used, step 3(ii) will be excluded from the synthetic procedure.
  • the protected amino acid preferably using Benzyloxycarbonyl- as Na-amino protecting group, is activated as a mixed anhydride with isobutyloxycarbonylchloride, or a similar type of chloroformate.
  • the method employed is based on the general method reviewed by J. Meienhofer in The Peptides, Vol.l, Eds.: E. Gross & J. Meienhofer, Academic Press, Inc, London 1979, pp. 264-309. 12
  • the activation time can be extended to at least 30 min at a temperature about 0 - -15°C, contrary to the recommended 1-2 min at -15°C.
  • strictly anhydrous conditions are not necessary as otherwise is recommended. This allows the present method to be used for large scale production where the longer reaction times allow a safe and reproducible process to be carried out.
  • the stereochemical integrity has been completely maintained and the chemical purity as well as yields have been typically over 90%.
  • the generated mixed anhydride is coupled with the slow addition of the amino component (amino acid/ peptide amide or ester) at about 0 - -15°C and the reaction mixture is then allowed to reach 20-30°C in about 30-60 min. or longer before crystallization of the product is initiated directly from the reaction mixture.
  • R is an ester or an amide residue group
  • target compound (I) is a useful intermediate for the preparation of target compound (I).
  • Z-Phe(pF) (compound 1)(1 eq.) is first dissolved in acetone (4.7L/mole) and cooled before addition of IBK (0.9-1.2 eq.)(leq actual). The reaction is then controlled by the rate of addition (about 20 minutes) of NMM (N-methylmorpholine) (0.9-1.2 eq.) (leq actual). A reaction temperature between 0 and -15°C is recommended (from -9°C to -14°C actual) where the reaction occurs immediately upon addition of NMM, yet prevents the mixed anhydride from decomposing to rapidly.
  • H-Phe-OMe x HCI (0.9-1.3 eq.) (1.04 eq actual) is meanwhile mixed with acetone (2.6L/mole), neutralized with NMM (0.9-1.5 eq.) (1.04eq actual) and cooled to 0 - -20°C (about -10°C actual).
  • This slurry is upon completion of the activation added at a rate that maintains the temperature around -10°C (from -8°C to -13°C actual) (about 30 minutes), EtOAc (4L/mole) is then charged and the organic phase washed with water (2x2L/mole) followed by azeotrop distillation from ACN and dissolution in MeOH prior to the next step. 92% purity in a methanol slurry.
  • Ammonia is charged to the solution of compound 3 prepared in the previous step (about 8L MeOH/mole) at a pressure between 1-5 bar at 15 to 40°C and for more than 5 hours or until the reaction is close to completion (actual conversion 99%). Upon completion the ammonia is evaporated and the reaction cooled before filtration or centrifugation. The product is washed with MeOH and dried under vacuum at 20-50 °C. Yield 74% calculated from compound 1 (Z-Phe(pF) ) and 100% purity. 19
  • Compound 4 prepared in the previous step is mixed with DMF (4.2L/mole) and and a Pd/C catalyst(5% Pd actual content) is added (0.2-10% w/w / LEF-581) (7% actual) and the resulting mixture hydrogenated for more than 0.5 hours (1.2h actual) at 25°C and 3bar H 2 .
  • the reaction mixture is then filtered and cooled to about -15°C before the next step. 99.6% purity in solution.
  • Compound 4 is mixed with DMF (2-2.6L/mole actual runs) and a 5 % Pd/C (actual content) catalyst is added (0.2-10% w/w / compound 3) (6-7% actual) and the resulting mixture hydrogenated for more than 0.5 hours(l-2h actual run) at 20-40°C (20-25°C actual runs) and 3bar H 2 .
  • the reaction mixture is then filtered to remove the Pd/C before crystallizing the product by addition of EtOAc until all substance has crystallized (typically lOL/mole).
  • EtOAc typically lOL/mole
  • the free base compound I is dissolved in a mixture of water and acetone with one equivalent HCI added and clear filtered ( 146g/mole 25% HCl/H 2 O, 2L Acetone/mole in actual run).
  • the salt has a limited solubility in acetone and therefore the filter is washed once with an additional amount of the acetone/water(95:5) mixture (0.5L/mole).
  • the crystallization is initiated by a slow addition of acetone (3.4L/mole) at high agitation rate and then at least 1 % w/w of seeding crystals is added. After 30 minutes the first amount of MIBK (3L/mole) is slowly charged and left with slow stirring until the batch clearly thickens.
  • MIBK (3L/mole) is charged three additional times separated by 30-60 minutes while maintaining the reactor inner temperature at about 20°C.
  • the solid is then separated by centrifugation or filtration and washed with MIBK before drying under vacuum at 20-50°C for more than 16 hours or until the solvent levels are lower than specified in the release specifications.
  • Z-Phe(pF) (1 eq.) is first dissolved in acetonitrile (EtOAc)(1.7L/mole) and cooled before addition of /-Butylchloroformiate (0.9-1.2 eq.)(1.05eq actual).
  • the reaction is then controlled by the rate of addition, (about 20 minutes) 15 min actual, of N- Methylmorpholine (0.9-2.0 eq.) (1.4eq actual).
  • a reaction temperature between 0 and - 15°C is recommended (from -8°C to -11°C actual) where the reaction occurs immediately upon addition of N-Methylmorpholine, yet prevents the mixed anhydride from decomposing to rapidly.
  • H-Phe- ⁇ H 2 x HCI (0.9-1.3 eq.) (1.04 eq actual) is meanwhile dissolved in DMF (4.0L/mole), neutralized with N-Methylmorpholine (0.9- 1.5 eq.) ( 1.04eq actual) and cooled to 0 - -20°C (about -10°C actual). This slurry is upon completion of the activation added at a rate that maintains the temperature around -10°C (from -6°C to -13°C actual) (about 15 minutes) 8 min actual.
  • the product was crystallized from the reaction mixture by slow addition of 50% Ethanol water (3.6L/mole). After 30 min wait a total of 2.85L/mole water in three portions were charged with about 25 min wait between each addition and at temperature of about 20°C.
  • the crystals can after about 17 hours be filtered or centrifuged and washed with 50% Ethanol/water followed by several portions of acetonitrile before drying under vacuum at 20-60°C. Yield 90% and 99.9% purity.
  • Z-Phe(pF)-Phe-NH 2 prepared in the previous step is mixed with DMF (3.5L/mole) and a Pd/C catalyst (5% Pd actual content) is added (0.2-10% w/w / LEF-582) (5% actual) and 28
  • the resulting mixture hydrogenated for more than 0.5 hours (1.3h actual) at 25-30°C and about 3bar H .
  • the reaction mixture is then filtered and cooled to about -15°C before the next step. 99.6% purity in solution and >99% conversion of starting material.
  • Methylmorpholine (0.9-2.0 eq.) (1.2eq used) was then added in a similar manner as described above for the preparation of Z-Phe(pF)-Phe- ⁇ H 2 .
  • the solution of H-Phe(pF)- Phe-NH 2 (25L) was then charged during about 15 minutes (8min actual), maintaining the temperature around -10°C (from -8°C to -11°C actual). After completion of the coupling the product was crystallized from the reaction mixture by slow addition of water
  • Z-D-Ala-Phe(pF)-Phe-NH 2 prepared in the previous step is mixed with DMF (2.9L/mole) and a Pd/C catalyst (5% Pd actual content) is added (0.2-10% w/w / compound 3)(5% actual) and the resulting mixture hydrogenated for more than 0.5 hours (3h actual) at 25- 35°C and about 3bar H .
  • the reaction mixture is then filtered and cooled to about -15°C before the next step. Purity 99.4%. Conversion of starting material >99% 29
  • the product was crystallized from the reaction mixture at about 20-45°C by slow addition of acetonitrile and water (3.4L/mole MeCN + 0.9L/mole 15% NH 3 in H 2 O hold 5min and seed, hold 4-24h, then add a total of 13.9L/mole H 2 O in four portions with about 30min or longer hold in between each. Filter or centrifuge and wash first with water and then MeCN before optional drying under vacuum at 20-60°C.
  • Z-Tyr-D-Ala-Phe(pF)-Phe-NH 2 is mixed with DMF (2.6L/mole actual run) and a 5 % Pd/C (actual content) catalyst is added (0.2-10% w/w / compound 3) (6.4% actual) and the resulting mixture hydrogenated for more than 0.5 hours(1.8h actual run) at 20-40°C (20- 25°C actual runs) and about 3bar H 2 .
  • the reaction mixture is then filtered to remove the Pd C before crystallizing the product by addition of EtOAc until all substance has crystallized (typically about 14L/mole).
  • the solid is separated by filtration or centrifugation 30
  • the free base H-Tyr-D-Ala-Phe(pF)-Phe-NH 2 is dissolved in a mixture of water and acetone with one equivalent HCI added and clear filtered (146g/mole 25% HCl/H 2 O, 2L Acetone/mole in actual run).
  • the salt is almost insoluble in acetone and therefore the filter is washed once with an additional amount of the acetone/water(95:5) mixture (0.5L/mole).
  • the crystallization is initiated by a slow addition of acetone (3.4L/mole) at high agitation rate and then about 1 % w/w of seeding crystals is added.
  • Product that fail the specifications for the drug substance may be recrystallized by the same procedure as described above for the crystallization of the compound I, but without the HCI addition.
  • NMR spectra were obtained on a solution of 36mg of the compound in approx. 0.7 ml DMSO-d 6 (99.95 atom-% D) at 27.0° C on a Varian UNITY plus 400 MHz instrument.
  • Chemical shift reference for proton spectra was the middle peak of the DMSO-c multiplet taken as 2.49 ppm.
  • Reference for carbon spectra was the middle peak of the DMSO-d multiplet taken as 39.5 ppm.
  • Atom numbering used in assignment is arbitrary and refers to the figure above.
  • PROTON SPECTRA The one dimensional proton spectrum allows groupwise assignment of alpha protons (3.9 4.4 ppm), benzyl-CH2 (2.6-3.1 ppm), amide-NH and phenol-OH (8.2-8.5 ppm) and also specific assignment for Ala-CH3 (I4-CH3) (0.74 ppm).
  • the two dimensional DQFCOS Y spectrum allows for groupwise assignment of the spin systems (alpha, beta and NH protons) in each amino acid residue, and groupwise assignment of aryl protons in each aromatic ring. All protons in the Ala residue can also be specifically assigned.
  • the one dimensional carbon spectrum allows for groupwise assignment of alpha carbons, benzyl-CH2, carbonyls and aryl carbons and of course specific assignment of C-14.
  • the APT spectrum allows assignment of CH-multiplicity for each carbon. Line splittings due to C-F couplings allows specific assignment of the carbons in the fluoroaromatic ring.
  • the two dimensional carbon-proton correlated (HMQC) spectrum gives a correlation between protonated carbons and all directly bound protons. All protonated carbons in the Ala residue can be specifically assigned.
  • the two dimensional carbon-proton multiple-bond correlated (HMBC) spectrum gives a correlation between carbons and protons situated two to three bonds apart. This allows assignment of amino acid sequence via alpha hydrogens and the carbonyl group of the neighboring amino acid residue (three-bond correlation), as well as via NH and the carbonyl group of the neighboring amino acid residue (two-bond correlation). Similarly two- and three-bond correlations between benzyl-Qf ⁇ .and aryl carbons as well as between aryl protons and benzyl-CH2 allows specific assignment of aryl protons and carbons of the individual aromatic amino acids.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses a new and improved process for the preparation of the tetrapeptide H-Tyr-D-Ala-Phe(F)-Phe-NH2 which is a peptide of formula (I) or a pharmaceutically acceptable salt thereof, as well as new intermediates in the preparation thereof. The novel process is suitable for large scale production.

Description

PROCESS FOR THE PREPARATION OF A TETRAPEPTIDE
FIELD OF THE INVENTION
The present invention is directed to a new process for the preparation of a tetrapeptide, more specifically the tetrapeptide H-Tyr-D-Ala-Phe(pF)-Phe- NH2, or a pharmaceutically acceptable salt thereof. In further aspects, the present invention also relates to new intermediates used in process.
BACKGROUND AND PRIOR ART
The present invention relates to a new process for the preparation of the peptide H-Tyr-D- Ala-Phe(pF)-Phe-NH2' or a pharmaceutically acceptable salt thereof.
WO 97/07129 discloses a process for producing inter alia the peptide H-Tyr-D-Ala-Phe(pF)-Phe-NH2. The peptide H-Tyr-D-Ala-Phe(pF)-Phe-NH is also disclosed in WO 97/07130. Said peptide exhibits peripheral analgesic activity and selectivity for the μ subtype of opioid receptors, and is suitable in particularly in pain therapy. Furthermore, it is prepared using solid phase synthesis according to procedures well established in the art. The drawback with solid phase synthesis, which is a common and well established method for peptide synthesis, is that it is difficult to use for large scale production, in addition to being expensive.
The process of the present invention provides the tetrapeptide H-Tyr-D-Ala-Phe(pF)-Phe- NH2 with a higher purity, in a more cost effective and environmentally better way compared to methods known in the art. Furthermore, the process of the present application provides the product in a higher yield.
Thus, the object of the present invention is to provide a novel process suitable for use in large scale synthesis. A further object of the present invention is to provide a process containing as few reaction steps as possible. OUTLINE OF THE INVENTION
The present invention provides a new process for large scale preparation of the peptide H- Tyr-D-Ala-Phe(pF)-Phe-NH2, which is a peptide of the formula (I)
(I)
or a pharmaceutically acceptable salt thereof.
The process according to the present invention for preparing a compound of the formula (I) above, comprises the following reaction steps;
Step l
(i) A coupling step wherein an activated ?-fluorophenylalanine derivative (HI),
(III)
A-
wherein
A is an amino protecting group, and
R is an activating agent residue group; previously prepared by a pre-activation step or generated in situ, is reacted with the amino group of phenylalanine, wherein the carboxyl group is protected as an ester or amide, i.e. a compound of the formula Phe-R , wherein R is the ester or amide residue group, in the presence of a solvent, providing a protected dipeptide derivative (TV)
(IV)
wherein
A is an amino protecting group, and R is an ester or an amide residue group;
(ii) A deprotection step wherein a protected dipeptide derivative (TV) prepared in the previous step, is deprotected by either catalytic hydrogenation, base or acid treatment, depending on the amino protecting group used, providing the dipeptide derivative (5),
wherein
R is an ester or an amide residue group;
Step 2
(i) A coupling step wherein an activated alanine derivative (VII),
H3Q
(VII) H O
wherein
A is an amino protecting group, and
R is an activating agent residue group; previously prepared by a pre-activation step or generated in situ, is reacted with the product of step 1, i.e. the dipeptide derivative (5) in the presence of a solvent, providing the protected tripeptide derivative(VIII)
JA
"H o ,. (VIII)
wherein A is an amino protecting group, and
R is an ester or an amide residue group; (ii) A deprotection step wherein a protected tripeptide derivative (VIII) prepared in the previous step, is deprotected either by catalytic hydrogenation or acid treatment, depending on the amino protecting group used, providing the tripeptide derivative (9)
O
H„N- irV (9)
y>
wherein
R is an ester or an amide residue group;
Step 3
(i) A coupling step wherein an activated tyrosine derivative (X),
(X)
A-
wherein
A is an amino protecting group, R is an activating agent residue group, and
2 R is H or a benzyl-like group; previously prepared by a pre-activation step or generated in situ, is reacted with the tripeptide derivative (9) and being the product of step 2, in the presence of a solvent, providing the protected tetrapeptide derivative (XI)
A- (XI)
R1
O T O f
wherein
A is an amino protecting group, and
R is an ester or an amide residue group;
(ii) A optional transformation step performed if the protected tetrapeptide derivative (XI) prepared in the previous step (i) is an ester, wherein the ester compound (XI) is reacted with ammonia in an organic alcohol , preferably ammonia in methanol, providing the protected dipeptide derivative (XII),
(XII)
(iii) A deprotection step wherein a protected tetrapeptide derivative (XII) is deprotected either by catalytic hydrogenation, base or acid treatment, depending on the amino protecting group used, providing the final tetrapeptide (I), which optionally may be converted to a salt of the tetrapeptide (I).
The peptide H-Tyr-D-Ala-Phe(pF)-Phe-NH2 (I), may if desired be reacted with a pharmaceutically acceptable acid, such as AcOH, H3PO4, citric acid, lactic acid and HCI. HCI is the preferred acid to use in accordance with the present invention. Possible salts which may be used are described in S. M. Berge, L. D. Bighley and D. C. Monkhouse, J. Pharmaceut. Sci, 66(1977) 1-19.
The process according to the present invention described above can therefore schematically be described as comprising the following steps;
Step 1
(i) A coupling step, (ii) A deprotection step,
Step 2 (i) A coupling step, (ii) A deprotection step
Step 3
(i) A coupling step, (ii) An optional transformation step, (iii) A deprotection step
The optional transformation step described above in step 3(ii) could instead be performed after the coupling step (i) in Step 1 or step 2. Preferably the transformation step is performed after the coupling step (i) in step 1. The preferred way of performing the process of the present invention could therefore schematically be described as comprising the following steps;
Step 1 (i) A coupling step,
(ii) An optional transformation step, (iii) A deprotection step,
Step 2 (i) A coupling step, (ii) A deprotection step
Step 3
(i) A coupling step, (ii) A deprotection step
The N -amino protecting group may be selected from any protecting group suitable in peptide synthesis, such as tert-butoxycarbonyl (Boc) or benzyloxycarbonyl, often abbreviated Z-, just to mention two possible amino protecting groups. However, benzyloxycarbonyl is particularly preferred to use for the present synthesis since it is easily removed by catalytic hydrogenation, and contrary to the protecting group Boc, it does not require neutralization of the liberated amine. Suitable amino and carboxyl protecting groups which may be used in accordance with the present invention will be appreciated by a person skilled in the art. Reference is made to J. Meienhofer in The Peptides, Vol.l, Eds.: E. Gross & J. Meienhofer, Academic Press, Inc, London 1979, pp. 264-309; The peptides, Vol. 1-9, E. Gross & J. Meienhofer, Eds., Academic Press Inc., London, 1979-1987; Houben-Weyl, Methoden der organischen Chemie, E. Muller, ed., Vol. 15, Partl-II, Thieme, Stuttgart 1974; and M. Bodanszky, Principles of peptide Synthesis, Springer Verlag, Berlin 1984. The pre-activation step preceding Step 1-3, or the in situ generation of the activated activated amino acid derivative, is achieved by reacting an amino acid, wherein the amino function has been protected by a suitable protecting group, such as tert-butoxycarbonyl (Boc) or benzyloxycarbonyl (Z), which are either commercially available or available by techniques known in the art, with an activating agent in the presence of a tertiary amine and an organic solvent, providing the activated amino acid derivative. A schematic representation of a pre-activation step is shown below
activating agent
A-
(II) (in) aminoacid derivative activated aminoacid derivative
wherein
A is an amino protecting group, and
R is an activating agent residue group;
For the coupling step, in Step 1-3 described above, a variety of powerful solvents may be used, as long as the amino component is essentially soluble and available for immediate reaction with the activated peptide derivative. Examples of suitable solvents for the coupling step are acetone, acetonitrile, DMF, N-methyl pyrrolidone (NMP) and EtOAc, or mixtures thereof.
As used herein, the term " benzyl-like group " denotes any substituted or un-substituted benzyl group that is hydrogenolyzed under similar reaction conditions as the benzyloxycarbonyl group. 10
The term "pF" denotes a αra-fluoro substituent.
Possible as well as preferred reagents and reaction conditions in each step are the following.
The pre-activation step
Suitable activating agents may be selected from those that generates any of the commonly used activated amino acid derivatives including, but not limited to, carbodiimides, activated esters, azide, or anhydrides. Isobutylchloroformiate (iBuOCOCl) is the preferred activating agent. When isobutylchloroformiate (iBuOCOCl) is the activating agent, the activated peptide derivative will have the following structure, exemplified on D-alanine,
H3C O-iBu
A^ ΗN o y
The tertiary amine may be selected from any tertiary amine. However, NMM (N-methylmorpholine), di-isopropylethylamine and triethylamine are preferred. Furthermore, a secondary amine which is sterically hindered may also be used.
The organic solvent may be any organic solvent known to a person skilled in the art to be suitable in peptide chemistry. However, ethyl acetate, acetonitrile, acetone and tetrahydrofurane are preferred solvents in the pre-activation step.
The coupling step; Step Hi), step 2(i) and step 3 (i)
The solvent used for the coupling step may be selected from a variety of solvents, as long as the amino component is essentially soluble and available for immediate reaction with the O 99/47548
11
activated amino acid residue. Examples of suitable solvents for the coupling steps are acetone, acetonitrile, DMF, N-methyl pyrrolidone (NMP) and EtOAc, or mixtures thereof, of which acetone, EtOAc, NMP and DMF are preferred.
Any temperature where the activated amino acid derivative is not degraded or the reaction rate is too slow may be used. The preferred range is from 0°C to -20°C, and particularly preferred is from -5°C to -15°C. The rate of addition is adjusted so that the preferred temperature is maintained.
The deprotection step; Step l(ii), step 2(ii), and step 3 (iii)
The catalyst used for hydrogenation may be selected from a great variety of catalysts as will be appreciated by a person skilled in the art. However 5% Pd on carbon is preferred. Any solvent that can dissolve at least some of the peptide is possible to use except ketones, such as acetone, or those solvents that poison the catalyst or react with the components of the reaction. The choice of solvent will be appreciated by a person skilled in the art. DMF is the preferred solvent.
The optional Step 3(ii) is only required if the protected tetrapeptide derivative (XI) prepared in step 3(i) is an ester. Thus, if an amide of phenylalanine is used, step 3(ii) will be excluded from the synthetic procedure.
If an acid is used for removal of the α-protecting group, an equivalent molar amount of a base is required to deprotonate the amino group of the peptide derivative.
In a preferred embodiment of the present invention the protected amino acid, preferably using Benzyloxycarbonyl- as Na-amino protecting group, is activated as a mixed anhydride with isobutyloxycarbonylchloride, or a similar type of chloroformate. The method employed is based on the general method reviewed by J. Meienhofer in The Peptides, Vol.l, Eds.: E. Gross & J. Meienhofer, Academic Press, Inc, London 1979, pp. 264-309. 12
We have surprisingly found that the activation time can be extended to at least 30 min at a temperature about 0 - -15°C, contrary to the recommended 1-2 min at -15°C. We also found that strictly anhydrous conditions are not necessary as otherwise is recommended. This allows the present method to be used for large scale production where the longer reaction times allow a safe and reproducible process to be carried out. The stereochemical integrity has been completely maintained and the chemical purity as well as yields have been typically over 90%. The generated mixed anhydride is coupled with the slow addition of the amino component (amino acid/ peptide amide or ester) at about 0 - -15°C and the reaction mixture is then allowed to reach 20-30°C in about 30-60 min. or longer before crystallization of the product is initiated directly from the reaction mixture.
We have also surprisingly found that when using the present method, if appropriately selected solvent combinations is used, there is no need for a separate washing step prior to crystallization. DMF, acetonitrile, EtOAc and water are preferably used. A controlled crystallization not only achieves an excellent purification but also shortens the filtering or centrifugation time during work up as well as shortens the drying time, if dry intermediates are required. One important factor is to generate sufficiently large crystals with a relatively narrow size distribution not to block the filter medium or centrifugation cloth. It is very common for peptides in particular to generate gels or amorphous crystals that are almost impossible to filter.
The tripeptide derivative (9)
H.N
(9)
13
wherein
R is an ester or an amide residue group;
is a useful intermediate for the preparation of target compound (I).
DETAILED DESCRIPTION OF THE INVENTION
The preperation of the peptide H-Tyr-D-Ala-Phe(pF)-Phe-NH2 or a pharmaceutically acceptable salt thereof, will now be described in more detail by the following Examples, which however should not be construed as limiting the invention. Furthermore, Scheme 1 below provides a detailed overview of the synthetic route followed for the preparation of the peptide of the formula (I) according to the present invention using a phenylalanine derivative, wherein the carboxyl group is protected as an ester. Scheme 2 below provides a detailed overview of the synthetic route followed for the preparation of the peptide of the formula (I) according to the present invention using a phenylalanine derivative wherein the carboxyl group is protected as an amide. The compound numbers referred to in the detailed synthesis description in the Examples below, correspond to the compound numbering in Schemes 1 and 2.
14
Scheme 1
(i) CH:
F CH. iBuOCOCl Cl vx H3 Acetone 7 CH ' -10°C 3 (2)
20 mm V^ CH,
NMM Z-Phe(pF)-OCOOiBu
(i) Phe-OMe x HCL (ii) NM
(a)-10°C30min (b) 25 °C 1 h
CH,
(3)
Z-Phe(pF)-Phe-OMe
(4)
Z-Phe(pF)-Phe-NH2
15
Scheme 1 (cont'd)
(i) iBuOCOCl \ fj
H3Q (ϋ) NMM
H3Q
(6)
Z-D-Ala J Ti ACN CH 3
-10 °C 20 min y r CH,
(a)-10°C30mirv
(b) 25 °C 1 h (7) Z-D-Ala-OCOOiBu
ACN + DMF/ H-Phe(pF)-P e-NH2
H-D-Ala-Phe(pF)-Phe-NH2
O 99/47548
16
Scheme 1 (cont'd)
(i) iBuOCOCl (ii) NMM
ACN -10°C 20 min (a) -10 °C 30 min (b) 25 °C 1 h (11) Z-Tyr-OCOOiBu
(10) Z-Tyr H-D-Ala-Phe(pF)-Phe-NH2 (9) kJ firY o T
CH, (12)
Z-Tyr-D-Ala-Phe(pF)-Phe-NH2
5 % Pd/C H2 'DMF
3 bar 25 °C 1 h
(I)
HCI/H20 Acetone MIBK
H-Tyr-D-Ala-Phe(pF)-Phe-NH2 x HCI 17
Ste l
(i) Preparation of Z-Phe(pF)-Phe-OMe (Compound 3 in Scheme 1)
3.5 mole scale
Z-Phe(pF) (compound 1)(1 eq.) is first dissolved in acetone (4.7L/mole) and cooled before addition of IBK (0.9-1.2 eq.)(leq actual). The reaction is then controlled by the rate of addition (about 20 minutes) of NMM (N-methylmorpholine) (0.9-1.2 eq.) (leq actual). A reaction temperature between 0 and -15°C is recommended (from -9°C to -14°C actual) where the reaction occurs immediately upon addition of NMM, yet prevents the mixed anhydride from decomposing to rapidly.
H-Phe-OMe x HCI (0.9-1.3 eq.) (1.04 eq actual) is meanwhile mixed with acetone (2.6L/mole), neutralized with NMM (0.9-1.5 eq.) (1.04eq actual) and cooled to 0 - -20°C (about -10°C actual). This slurry is upon completion of the activation added at a rate that maintains the temperature around -10°C (from -8°C to -13°C actual) (about 30 minutes), EtOAc (4L/mole) is then charged and the organic phase washed with water (2x2L/mole) followed by azeotrop distillation from ACN and dissolution in MeOH prior to the next step. 92% purity in a methanol slurry.
18
Shift Multiplicity Integral H
8.5 d 1
7.49 d 1
7.31 m 7
7.24 m 5
7.08 m 2
4.93 m 2
4.5 m 1
4.26 m 1 3 3..5588 ss 3
2.99 m 3 2.67 m 1
(ii) Preparation of Z-Phe(pF)-Phe-NH? (compound 4 in Scheme 1)
2.3-3.3 mole scale
Ammonia is charged to the solution of compound 3 prepared in the previous step (about 8L MeOH/mole) at a pressure between 1-5 bar at 15 to 40°C and for more than 5 hours or until the reaction is close to completion (actual conversion 99%). Upon completion the ammonia is evaporated and the reaction cooled before filtration or centrifugation. The product is washed with MeOH and dried under vacuum at 20-50 °C. Yield 74% calculated from compound 1 (Z-Phe(pF) ) and 100% purity. 19
Shift Multiplicity Integral H
8.05 d 1
7.49 d 1
7.24 m 11
7.07 m 3
4.94 m 2
4.46 m 1
4.21 m 1 3 3..0000 mm 1
2.88 m 1 2.66 m 1
Preparation of H-Phe(pF)-Phe-NH2 (compound 5 in Scheme 1)
4.3 mole scale
Compound 4 prepared in the previous step is mixed with DMF (4.2L/mole) and and a Pd/C catalyst(5% Pd actual content) is added (0.2-10% w/w / LEF-581) (7% actual) and the resulting mixture hydrogenated for more than 0.5 hours (1.2h actual) at 25°C and 3bar H2. The reaction mixture is then filtered and cooled to about -15°C before the next step. 99.6% purity in solution.
Step 2
(i) Preparation of Z-D-Ala-Phe(pF)-Phe-NH? (compound 8 in Scheme 1)
4.4 mole scale
Z-D-Ala (compound 6) (1 eq.) was dissolved in acetonitrile (ACN) (2.3L/mole) and cooled before addition of IBK (0.9-1.2 eq.)(leq used). NMM (0.9-1.2 eq.) (leq used) was then 20
added in the same manner as described above for the preparation of compound 3. The solution of compound 5 (24.5L) was then charged during about 30 minutes, maintaining the temperature around -10°C (from -8°C to -14°C actual). After completion of the coupling the product was crystallized from the reaction mixture by slow addition of water (3x3.6L/mole + lx 1.3L/mole) with about 25 min wait between each addition and at a starting temperature of about 30°C and an ending temp of about 20°C. The crystals can then be centrifuged and washed with water/acetonitrile (4:1) before drying under vacuum at 20-50°C. Yield 90% and 99.5% purity.
Shift Multiplicity Integral H
8.14 d 1
8.05 d 1
7.43 d 1
7.29 m 12
7.05 m 2
5.01 m 2
4.44 m 2
4.01 m 1
2.92 m 3
2.73 m 1 0.96 d 3
21
Preparation of H-D-Ala-Phe(pF)-Phe-NH2 (compound 9 in Scheme 1)
Compound 8 prepared in the previous step is mixed with DMF (4.2IVmole) and a Pd/C catalyst (5% Pd actual content) is added (0.2-10% w/w / compound 3)(7% actual) and the resulting mixture hydrogenated for more than 0.5 hours (1.2h actual) at 25°C and 3bar H . The reaction mixture is then filtered and cooled to about -15°C before the next step. Purity 97%. Conversion of starting material >98%
Step 3
(i) Preparation of Z-Tyr-D-Ala-Phe(pF)-Phe-NH» (compound 12 in Scheme 1)
4.1 mole scale
This coupling utilized the same method as the previous two couplings. Z-Tyr (compound 10) (1 eq.) was dissolved in ACN (2.3L/mole)and cooled before addition of IBK (0.9-1.2 eq.). NMM (0.9-1.2 eq.) was then added in the same manner as described above under compound 3. The solution of compound 3 from the previous step was then charged during about 30 minutes, maintaining the temperature around -10°C (from -7°C to -14°C actual). After completion of the coupling the product was crystallized from the reaction mixture by slow addition of acetonitrile and water (2L/mole ACN + 0.3L/mole 25% NH3 in H2O .hold 2h, add 1.5L/mole ACN:H2O (1:1), hold lh, increase temp to 35°C, add seeding crystals (about 1% w/w), hold lh, add 1.3L/mole ACN:H2O (1:1), hold lh, add 1.2L/mole H2O and hold 0.5h at 35°C, add 1.2L/mole H2O and hold 2h at 20°C, add 1.2L/mole H2O and hold lh at 20°C and add 1.2L mole H2O and hold 0.5h at 20°C. Centrifuge and wash first with water and then ACN before drying under vacuum at 20-50°C. Yield 81% calculated from compound 8. 98.4% pure. 22
Shift Multiplicity ntegral H
9.18 s
8.18 d
8.11 d
8.05 d
7.43 d
7.24 m
7.04 m 4
66..6633 d 2
4.92 m 2
4.45 m 2
4.22 m 2
3.00 m 1
22..8833 mm 1
2.64 m 1 0.89 d 3
(ii) Preparation of H-Tyr-D-Ala-Phe(pF)-Phe-N-Bk (compound I in Scheme 1)
3.1 and 3.2 mole scale
Compound 4 is mixed with DMF (2-2.6L/mole actual runs) and a 5 % Pd/C (actual content) catalyst is added (0.2-10% w/w / compound 3) (6-7% actual) and the resulting mixture hydrogenated for more than 0.5 hours(l-2h actual run) at 20-40°C (20-25°C actual runs) and 3bar H2. The reaction mixture is then filtered to remove the Pd/C before crystallizing the product by addition of EtOAc until all substance has crystallized (typically lOL/mole). The solid is separated by filtration or centrifugation and washed with EtOAc prior to drying under vacuum at 20-50°C. 23
Preparation of H-Tyr-D-Ala-Phe(pF)-Phe-NH? hydrochloride
2.1 mole scale
The free base compound I is dissolved in a mixture of water and acetone with one equivalent HCI added and clear filtered ( 146g/mole 25% HCl/H2O, 2L Acetone/mole in actual run). The salt has a limited solubility in acetone and therefore the filter is washed once with an additional amount of the acetone/water(95:5) mixture (0.5L/mole). The crystallization is initiated by a slow addition of acetone (3.4L/mole) at high agitation rate and then at least 1 % w/w of seeding crystals is added. After 30 minutes the first amount of MIBK (3L/mole) is slowly charged and left with slow stirring until the batch clearly thickens. MIBK (3L/mole) is charged three additional times separated by 30-60 minutes while maintaining the reactor inner temperature at about 20°C. The solid is then separated by centrifugation or filtration and washed with MIBK before drying under vacuum at 20-50°C for more than 16 hours or until the solvent levels are lower than specified in the release specifications.
24
Scheme 2
CH,
H3C
H3C
Cl
Z-Phe(pF) iBuOCOCl NMM
EtOAc
CH,
,N.
N gMM
1 n°°9 , 25°C 10 mm -H -jr,
EtOAc + DMF
H2 Pd/C
DMF 25°C -1h
Z-Phβ(pF)-Phe-NH2
P e(pF)-Ph^NH2 (13) (14) 25
Scheme 2 (cont'd)
OH
H3C i) iBuOCOCl CH, ii) NMM
CH,
NH MeCN -10°C o y CH,
M H y O yn
Z-D-Ala Z-D-Ala-OCOOiBu
H-Phe(pF)-Phe-NH2 (14) i) -10°C, 10 min ii) 25°C, 1h
MeCN
H-D-Ala-Phe(pF)-Phe-NH2
5% Pd/C DMF (16)
(15)
26
Scheme 2 (cont'd)
i) iBuOCOCl ii) NMM MeCN -ιo°c o
Z-Tyr
H-D-Ala-Phe(pF)-Phe-NH2 (16) i) -10°C, 10 min ii) 25°C, lh MeCN
n r^πrV "
Z-Tyr-D-Ala-Phe(pF)-Phe-NH2 (17)
5% Pd/C DMF
H-Tyr-D-Ala-Phe(F)-Phe-NH2 (I)
Aceton
HCI 3% H20 MIBK
Z-Tyr-D-Ala-Phe(pF)-Phe-NH2x HCI
27
Ste l
(i) Preparation of Z-Phe(pF)-Phe-NH2 (Compound 13 in Scheme 2)
6.7 mole scale
Z-Phe(pF) (1 eq.) is first dissolved in acetonitrile (EtOAc)(1.7L/mole) and cooled before addition of /-Butylchloroformiate (0.9-1.2 eq.)(1.05eq actual). The reaction is then controlled by the rate of addition, (about 20 minutes) 15 min actual, of N- Methylmorpholine (0.9-2.0 eq.) (1.4eq actual). A reaction temperature between 0 and - 15°C is recommended (from -8°C to -11°C actual) where the reaction occurs immediately upon addition of N-Methylmorpholine, yet prevents the mixed anhydride from decomposing to rapidly.
H-Phe-ΝH2 x HCI (0.9-1.3 eq.) (1.04 eq actual) is meanwhile dissolved in DMF (4.0L/mole), neutralized with N-Methylmorpholine (0.9- 1.5 eq.) ( 1.04eq actual) and cooled to 0 - -20°C (about -10°C actual). This slurry is upon completion of the activation added at a rate that maintains the temperature around -10°C (from -6°C to -13°C actual) (about 15 minutes) 8 min actual.
After completion of the coupling the product was crystallized from the reaction mixture by slow addition of 50% Ethanol water (3.6L/mole). After 30 min wait a total of 2.85L/mole water in three portions were charged with about 25 min wait between each addition and at temperature of about 20°C. The crystals can after about 17 hours be filtered or centrifuged and washed with 50% Ethanol/water followed by several portions of acetonitrile before drying under vacuum at 20-60°C. Yield 90% and 99.9% purity.
Preparation of H-Phe(pF)-Phe-ΝH? (compound 14 in Scheme 2)
6.7 mole scale
Z-Phe(pF)-Phe-NH2 prepared in the previous step is mixed with DMF (3.5L/mole) and a Pd/C catalyst (5% Pd actual content) is added (0.2-10% w/w / LEF-582) (5% actual) and 28
the resulting mixture hydrogenated for more than 0.5 hours (1.3h actual) at 25-30°C and about 3bar H . The reaction mixture is then filtered and cooled to about -15°C before the next step. 99.6% purity in solution and >99% conversion of starting material.
Step 2
(i) Preparation of Z-D-AIa-Phe(pF)-Phe-NH? (compound 15 in Scheme 2)
5.9 mole scale
Z-D-Ala-OH (compound x) (1.03 eq. used) was dissolved in acetonitrile (1.9L/mole) and cooled before addition of /-Butylchloroformiate (0.9- 1.2 eq.)( 1.07eq used). N-
Methylmorpholine (0.9-2.0 eq.) (1.2eq used) was then added in a similar manner as described above for the preparation of Z-Phe(pF)-Phe-ΝH2. The solution of H-Phe(pF)- Phe-NH2 (25L) was then charged during about 15 minutes (8min actual), maintaining the temperature around -10°C (from -8°C to -11°C actual). After completion of the coupling the product was crystallized from the reaction mixture by slow addition of water
(4xl.9L/mole) with about 15-30 min wait between each addition and at a temperature of about 20°C. The crystals can then be filtered or centrifuged and washed with water/acetonitrile (4: 1) followed by acetonitrile before an optional drying under vacuum at 20-60°C. Yield calculated from Z-Phe(pF)-Phe-NH2 93.8% and 99.6% purity.
Preparation of H-D-Ala-Phe(pF)-Phe-NH2 (compound 16 in Scheme 2)
5.5 mole scale
Z-D-Ala-Phe(pF)-Phe-NH2 prepared in the previous step is mixed with DMF (2.9L/mole) and a Pd/C catalyst (5% Pd actual content) is added (0.2-10% w/w / compound 3)(5% actual) and the resulting mixture hydrogenated for more than 0.5 hours (3h actual) at 25- 35°C and about 3bar H . The reaction mixture is then filtered and cooled to about -15°C before the next step. Purity 99.4%. Conversion of starting material >99% 29
Step 3
(i) Preparation of Z-Tyr-D-Ala-Phe(pF)-Phe-NH2 (compound 17 in Scheme 2)
5.5 mole scale
This coupling utilized a similar method as the previous two couplings. Z-Tyr
(compound x) (1.05 eq.) was dissolved in MeCN (1.9L/mole)and cooled before addition of -Butylchloroformiate (0.9-1.2 eq.)(1.05 actual). N-Methylmorpholine (0.9-2.0 eq.)(1.3 actual) was then added in a similar manner as described above for the preparation of Z- Phe(pF)-Phe-ΝH2. The solution of H-D-Ala-Phe(pF)-Phe-NH2 from the previous step was then charged during about 20 minutes (6min actual), maintaining the temperature around - 10°C (from -8°C to -9°C actual). After completion of the coupling the product was crystallized from the reaction mixture at about 20-45°C by slow addition of acetonitrile and water (3.4L/mole MeCN + 0.9L/mole 15% NH3 in H2O hold 5min and seed, hold 4-24h, then add a total of 13.9L/mole H2O in four portions with about 30min or longer hold in between each. Filter or centrifuge and wash first with water and then MeCN before optional drying under vacuum at 20-60°C.
Yield 87.7% calculated from Z-D-Ala-Phe(pF)-Phe-NH2 and 95.1% pure. The yield and purity were found to be increased by heating the reaction to about 60°C with addition of ammonia to a pH of about 9 for two hours. This will convert the major impurity, Z-Tyr(O-( -Butyloxycarbonyl))-o-Ala-Phe(pF)-Phe-NH2, to product.
(ii) Preparation of H-Tyr-D-Ala-Phe(pF)-Phe-NH^ (compound I in Scheme 2)
5.4 mole scale
Z-Tyr-D-Ala-Phe(pF)-Phe-NH2 is mixed with DMF (2.6L/mole actual run) and a 5 % Pd/C (actual content) catalyst is added (0.2-10% w/w / compound 3) (6.4% actual) and the resulting mixture hydrogenated for more than 0.5 hours(1.8h actual run) at 20-40°C (20- 25°C actual runs) and about 3bar H2. The reaction mixture is then filtered to remove the Pd C before crystallizing the product by addition of EtOAc until all substance has crystallized (typically about 14L/mole). The solid is separated by filtration or centrifugation 30
and washed with EtOAc prior to drying under vacuum at 20-50°C. Purity 96.7%. Conversion of starting material >99%
Preparation of H-Tyr-D-Ala-Phe(pF)-Phe-NH? hydrochloride
4.6 mole scale
The free base H-Tyr-D-Ala-Phe(pF)-Phe-NH2 is dissolved in a mixture of water and acetone with one equivalent HCI added and clear filtered (146g/mole 25% HCl/H2O, 2L Acetone/mole in actual run). The salt is almost insoluble in acetone and therefore the filter is washed once with an additional amount of the acetone/water(95:5) mixture (0.5L/mole). The crystallization is initiated by a slow addition of acetone (3.4L/mole) at high agitation rate and then about 1 % w/w of seeding crystals is added. After 30 minutes the first amount of MIBK (3L/mole) is slowly charged and left with slow stirring until the batch clearly thickens. MIBK (3L/mole) is charged three additional times separated by 30-60 minutes while maintaining the reactor inner temperature at about 20°C. The solid is then separated by centrifugation or filtration and washed with MIBK before drying under vacuum at 20- 50°C for more than 16 hours or until the solvent levels are lower than specified in the release specifications. Yield 95.8% and a purity of 99.8%.
Reprocessing
Product that fail the specifications for the drug substance may be recrystallized by the same procedure as described above for the crystallization of the compound I, but without the HCI addition. 31
Assignment of NMR spectra for H-Tyr-D-Ala-Phe(F)-Phe-NH^x HCI. i.e for compound I in its hydrochloride form.
NMR spectra were obtained on a solution of 36mg of the compound in approx. 0.7 ml DMSO-d6 (99.95 atom-% D) at 27.0° C on a Varian UNITY plus 400 MHz instrument. Chemical shift reference for proton spectra was the middle peak of the DMSO-c multiplet taken as 2.49 ppm. Reference for carbon spectra was the middle peak of the DMSO-d multiplet taken as 39.5 ppm.
0)
14 21
19 ^^ 24
22
Atom numbering used in assignment is arbitrary and refers to the figure above.
PROTON SPECTRA The one dimensional proton spectrum allows groupwise assignment of alpha protons (3.9 4.4 ppm), benzyl-CH2 (2.6-3.1 ppm), amide-NH and phenol-OH (8.2-8.5 ppm) and also specific assignment for Ala-CH3 (I4-CH3) (0.74 ppm).
The two dimensional DQFCOS Y spectrum allows for groupwise assignment of the spin systems (alpha, beta and NH protons) in each amino acid residue, and groupwise assignment of aryl protons in each aromatic ring. All protons in the Ala residue can also be specifically assigned. 32
CARBON SPECTRA
The one dimensional carbon spectrum allows for groupwise assignment of alpha carbons, benzyl-CH2, carbonyls and aryl carbons and of course specific assignment of C-14. The APT spectrum allows assignment of CH-multiplicity for each carbon. Line splittings due to C-F couplings allows specific assignment of the carbons in the fluoroaromatic ring.
TWO DIMENSIONAL HETEROCORRELATED SPECTRA
The two dimensional carbon-proton correlated (HMQC) spectrum gives a correlation between protonated carbons and all directly bound protons. All protonated carbons in the Ala residue can be specifically assigned.
The two dimensional carbon-proton multiple-bond correlated (HMBC) spectrum gives a correlation between carbons and protons situated two to three bonds apart. This allows assignment of amino acid sequence via alpha hydrogens and the carbonyl group of the neighboring amino acid residue (three-bond correlation), as well as via NH and the carbonyl group of the neighboring amino acid residue (two-bond correlation). Similarly two- and three-bond correlations between benzyl-Qfø .and aryl carbons as well as between aryl protons and benzyl-CH2 allows specific assignment of aryl protons and carbons of the individual aromatic amino acids.
In this way all (non-exchanging) protons and carbons in all four amino acid residues can be specifically assigned in an unambiguous way.
33
Table 1
Proton assignments
Chemical shift (ppm) Integral Multiplicity Assignment
9.4 IH s 30OH
8.48 IH d 9NH
8.37 IH d 1NH
8.35 IH d 8NH
8.26 2H s
7.53 IH s
7.28 2H m 18H, 19H
7.26 2H m 21H, 22H
7.22 2H m 6H, 7H
7.18 IH m 24H
7.12 IH s
7.04 2H m 10H, 11H
6.98 2H m 26H, 27H
6.68 2H m 28H, 29H
4.43 IH m IH
4.39 IH m 8H
4.26 IH m 9H
3.96 IH m 20H
3.39 HDO
3.02 IH m 12Hb
2.99 IH m 2Hb
2.87 2H m 23Ha, 23Hb
2.85 IH m 12Ha
2.67 IH m 2Ha
0.74 3H d 14H 34
Table 2
Carbon assignments
Chemical shift (ppm) Multiplicity Assignment Tc-F
172.99 s 13
171.08 s 5
170.81 s 3
167.39 s 17
162.11 s 15 241 Hz
159.70 s 15 241 Hz
156.50 s 30
137.98 s 16
133.96 s 4 3.1 Hz
133.93 s 4 3.1 Hz
131.16 d 6.7 8.4 Hz
131.08 d 6.7 8.4 Hz
130.46 d 26.27
129.26 d 18.19
128.09 d 21.22
126.30 d 24
124.73 s 25
115.16 d 28.29
114.63 d 10.11 21.3 Hz
114.41 d 10.11 21.3 Hz
54.33 d 8
54.01 d 1
53.37 d 20 35
Table 2 (contd.)
Carbon assignments
Chemical shift (ppm) Multiplicity Assignment Jc-F
47.96 d 9 37.57 t 12 36.83 t 2 36.17 t 23 18.45 g 14

Claims

36CLAIMS
1. A process for the preparation of the tetrapeptide H-Tyr-D-Ala-Phe(F)-Phe-NH2 of the formula (I)
(I)
or a pharmaceutically acceptable salt thereof, comprising the following steps:
(i) A coupling step wherein an activated tyrosine derivative (X),
(X)
A-
wherein
A is an amino protecting group, R is an activating agent residue group, and
2 R is H or a benzyl-like group; is reacted with the tripeptide derivative (9) 37
, (9) yy wherein
R is an ester or an amide residue group; in the presence of a solvent under standard conditions, providing the protected tetrapeptide derivative (XI)
A^ (XI)
wherein
A is an amino protecting group, and R is an ester or an amide residue group;
(ii) A deprotection step wherein the protected tetrapeptide derivative (XII) is deprotected either by catalytic hydrogenation, base or acid treatment under standard conditions in the presence of a solvent to give (I).
2. A process according to claim 1, characterized in comprising additional steps of: 38
(i) A coupling step wherein an activated alanine derivative (VII),
H3Q
O.
(VII)
A-
H
wherein
A is an amino protecting group, and R is an activating agent residue group; is reacted with the dipeptide derivative (5)
H N
(5)
wherein
R is an ester or an amide residue group in the presence of a solvent under standard conditions, providing the protected tripeptide derivative (VIII)
39
O
II
.H c -
CH, , (VIII)
wherein
A is an amino protecting group, and
R is an ester or an amide residue group;
(ii) A deprotection step wherein a protected tripeptide derivtive (VIII) prepared in the previous step, is deprotected either by catalytic hydrogenation, base or acid treatment, in the presence of a solvent under standard conditions, providing the tripeptide derivative (9)
O
H„N ■Λ R, (9)
yy
wherein
R is an ester or an amide residue group.
3. A process according to claim 2, characterized in comprising additional steps of:
(i) A coupling step wherein an activated -fluorophenylalanine derivative (III), 40
(III)
A-
wherein
A is an amino protecting group, and
R is an activating agent residue group; is reacted with the amino group of phenylalanine, wherein the carboxyl group is protected as an ester or amide, in the presence of a solvent under standard conditions, providing a protected dipeptide derivative (TV)
(IV)
wherein
A is an amino protecting group, and R is an ester or an amide residue group; (ii) A deprotection step wherein a protected dipeptide derivative (TV) prepared in the previous step, is deprotected by either catalytic hydrogenation, base or acid treatment, in the presence of a solvent under standard conditions, providing the dipeptide derivative (5), 41
(5)
wherein
R is an ester or an amide residue group.
4. A process according to claim 1-3, characterized in that one of the coupling steps (i) is followed by an optional transformation step, performed if the carboxyl group of the amino acid derivative is protected as an ester derivative, wherein the ester compound is reacted with ammonia in an organic alcohol.
5. A process according to claims 1-3, characterized in that the activated amino acid derivative used in at least one of the coupling steps is selected from a group consisting of a carbodiimide, an activated ester, an azide, or an anhydride.
6. A process according to claim 5, wherein the activating agent is isobutylchloroformiate.
7. A process according to any of claims 1-6, characterized in that the solvent used in at least one of the coupling steps is acetone, acetonitrile, NMP, DMF or EtOAc.
8. A process according to claims 1-3, wherein the solvent in the coupling step is DMF.
9. A process according to any of claims 1-3, characterized in that the deprotection step is performed using Pd on charcoal. 42
10. A process according to any of claims 1-9, characterized in that at least one of the reactions are performed at a temperature of from 0┬░C to -20 ┬░C.
1 1. A process according to claim 10, wherein the temperature is from -5 ┬░C to -15 ┬░C.
12. A peptide of the formula I
(I)
prepared according to the process of claim 1.
13. A peptide according to claim 12, in form of the hydrochloride salt.
14. A peptide derivative of the formula (9)
HΓÇ₧N (9)
wherein
R is an ester or an amide residue group.
EP99910934A 1998-03-16 1999-03-16 Process for the preparation of a tetrapeptide Withdrawn EP1062231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9800865 1998-03-16
SE9800865A SE9800865D0 (en) 1998-03-16 1998-03-16 New Process
PCT/SE1999/000414 WO1999047548A1 (en) 1998-03-16 1999-03-16 Process for the preparation of a tetrapeptide

Publications (1)

Publication Number Publication Date
EP1062231A1 true EP1062231A1 (en) 2000-12-27

Family

ID=20410566

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99910934A Withdrawn EP1062231A1 (en) 1998-03-16 1999-03-16 Process for the preparation of a tetrapeptide

Country Status (19)

Country Link
EP (1) EP1062231A1 (en)
JP (1) JP2002506880A (en)
KR (1) KR20010041888A (en)
CN (1) CN1300293A (en)
AU (1) AU2968899A (en)
BR (1) BR9908765A (en)
CA (1) CA2323678A1 (en)
EE (1) EE200000540A (en)
HU (1) HUP0102877A3 (en)
ID (1) ID26938A (en)
IL (1) IL138244A0 (en)
IS (1) IS5612A (en)
NO (1) NO20004613L (en)
PL (1) PL343277A1 (en)
SE (1) SE9800865D0 (en)
SK (1) SK13442000A3 (en)
TR (1) TR200002652T2 (en)
WO (1) WO1999047548A1 (en)
ZA (1) ZA200004376B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903291D0 (en) * 1999-09-15 1999-09-15 Astra Ab New process
WO2009076672A1 (en) * 2007-12-13 2009-06-18 Cytogel, Llc Advantageous salts of mu-opiate receptor peptides
CN104371002B (en) * 2013-06-20 2017-10-10 重庆理工大学 A kind of non-protein amino acid antibacterial peptide and its application
CN104478993B (en) * 2013-06-20 2017-10-10 重庆理工大学 A kind of non-protein amino acid antibacterial peptide and its application
CN103319568B (en) * 2013-06-20 2015-01-21 重庆理工大学 Non-protein amino acid antibacterial peptide and application for same
CN104783298A (en) * 2015-03-24 2015-07-22 湖州珍贝羊绒制品有限公司 Preparation and application of biological sterilizing composition and nanoemulsion thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9503924D0 (en) * 1995-08-18 1995-11-07 Astra Ab Novel opioid peptides
GB9516994D0 (en) * 1995-08-18 1995-10-18 Iaf Biochem Int Solution synthesis of peripheral acting analgestic opioid tetrapeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9947548A1 *

Also Published As

Publication number Publication date
NO20004613L (en) 2000-10-30
NO20004613D0 (en) 2000-09-15
HUP0102877A3 (en) 2002-02-28
IL138244A0 (en) 2001-10-31
JP2002506880A (en) 2002-03-05
TR200002652T2 (en) 2000-11-21
PL343277A1 (en) 2001-08-13
KR20010041888A (en) 2001-05-25
HUP0102877A2 (en) 2002-01-28
WO1999047548A1 (en) 1999-09-23
BR9908765A (en) 2000-11-07
IS5612A (en) 2000-08-30
CA2323678A1 (en) 1999-09-23
SK13442000A3 (en) 2001-04-09
ID26938A (en) 2001-02-22
SE9800865D0 (en) 1998-03-16
CN1300293A (en) 2001-06-20
ZA200004376B (en) 2001-10-31
EE200000540A (en) 2002-02-15
AU2968899A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
Stelakatos et al. On the Trityl Method for Peptide Synthesis1
EP1212350A1 (en) A process for the preparation of h-tyr-d-ala-phe(f)-phe-nh 2?
US6235876B1 (en) Liquid phase process for the preparation of GNRH peptides
CS241028B2 (en) Method of tripeptidamides production
JPH0832717B2 (en) Method for producing glutamine derivative
JPH0357118B2 (en)
EP1062231A1 (en) Process for the preparation of a tetrapeptide
JPS5973574A (en) Cyclic dipeptide
HU182866B (en) Process for preparing new tetrapeptide derivatives
EP0460446A1 (en) Coupling agent for peptide synthesis
US5965770A (en) N-aryloxycarbonyl amino acids and peptides and their derivatives
GB2130590A (en) Peptides
HU208838B (en) Method for producing peptones containing aza aminoacides by means of solid-phase synthesis
EP0410182A2 (en) A new technique for rapid peptide coupling
MXPA00008828A (en) Process for the preparation of a tetrapeptide
JP2693493B2 (en) Guanidine-related compound containing tetraphenylborate ion and process for producing the same
EP0896001A1 (en) Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
NZ523217A (en) Chemical process
CZ20003342A3 (en) Process for preparing tetrapeptide
JP4290844B2 (en) Method for producing theanine
JP3554399B2 (en) Peptide derivatives
JP2748897B2 (en) Novel arginine derivative and method for producing peptide using the same
JPH07316193A (en) Peptide derivative and use thereof
DK149631B (en) METHOD FOR PREPARING H-SAR-LIGHT-SAR-GLN-NH2
RU2111972C1 (en) METHOD OF SYNTHESIS OF δ-SLEEP PEPTIDE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001016

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20001016;LV PAYMENT 20001016;MK PAYMENT 20001016;RO PAYMENT 20001016;SI PAYMENT 20001016

17Q First examination report despatched

Effective date: 20010725

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SHIRE BIOCHEM INC.

18W Application withdrawn

Effective date: 20021223

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1032408

Country of ref document: HK